It’s been said before and it’s true: a healthy scalp is key to healthy hair. But for those dealing with pesky and sometimes painful scalp conditions like seborrheic dermatitis, that can be easier said ...

This article was reviewed by Knox Beasley, MD. Flakes on your scalp making you feel self-conscious? Let’s talk about seborrheic dermatitis vs dandruff. Whether your scalp feels like a snowglobe thanks ...

NEW YORK — Topical antifungals should no longer be considered a first-line therapy for seborrheic dermatitis for two reasons: Topical anti-inflammatories have replaced them, and rates of ...

Please provide your email address to receive an email when new articles are posted on . Malassezia yeast may not be the root cause of seborrheic dermatitis. A new study showed that Zoryve was a ...

Findings show that seborrheic dermatitis is a unique inflammatory skin disease with its own molecular signature Suggests skin barrier disruption in seborrheic dermatitis is distinct with its own ...

Please provide your email address to receive an email when new articles are posted on . Seborrheic dermatitis is often treated with topical antifungals or corticosteroids, which can be cumbersome on ...

Our stories are reviewed by medical professionals to ensure you get the most accurate and useful information about your health and wellness. For more information, visit our medical review board. This ...

Medically reviewed by Marisa Garshick, MD Wet dandruff symptoms may worsen with hormonal changes, stress, or cold, dry weather. Diagnosis involves checking the scalp for flaking, oiliness, and redness ...

Seborrheic dermatitis may disrupt the skin barrier, potentially exposing patients to other epithelial barrier diseases (EBDs) across various organ systems. A large cohort study found positive ...

The US Food and Drug Administration (FDA) has agreed to review a new drug application (NDA) for roflumilast foam 0.3% for treating seborrheic dermatitis in patients ages 9 years and older. If approved ...

Hot off its first approval this summer in psoriasis, Arcutis Biotherapeutics’ roflumilast foam 0.3%, approved in cream form under the brand name Zoryve, is out to prove it’s no one-trick pony in itch.